Overview of Molecular Detection Technologies for MET in Lung Cancer.

MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the proto-oncogene, including MET overexpression, the activation of mutations, mutations that lead to exon 14 skipping, gene amplifications, and fusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all known aberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the different aberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics.